<?xml version="1.0" encoding="UTF-8"?>
<p id="Par67">This is one of the first studies in the treatment-as-prevention field that has been designed to answer critical implementation questions (i.e. acceptance and retention among patients initiated on ART at higher CD4 thresholds), and determine the “real world” potential of this new prevention intervention [
 <xref ref-type="bibr" rid="CR9">9</xref>, 
 <xref ref-type="bibr" rid="CR16">16</xref>–
 <xref ref-type="bibr" rid="CR19">19</xref>]. In resource-limited countries, ministries of health need guidance on how to aggressively and effectively adopt the new guidelines and targets, and to understand what the changes will mean for their programs and budgets. As such, this study’s primary and secondary outcomes (Table 
 <xref rid="Tab2" ref-type="table">2</xref>) are structured to assess the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland’s public sector health system. 
</p>
